+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Market Spotlight: Gout

  • Report
  • 38 Pages
  • January 2021
  • Region: Global
  • Pharma Intelligence
  • ID: 4421370
Gout is a common form of inflammatory arthritis, characterized by acute but sporadic episodes of synovitis along with joint swelling and pain (acute gouty arthritis). It is a metabolic disorder caused by excess uric acid in the body. The excess uric acid or hyperuricemia forms tiny needle-shaped crystals that are deposited in the synovial fluid, bones, tendons, cartilage, bursas, or other sites, which can trigger an acute inflammatory attack. The inflammation usually subsides within one or two weeks, and the pain can be managed by taking anti-inflammatory medications.

Key Takeaways
  • The publisher estimates that in 2019, there were 35.4 million prevalent cases of gout in people aged 15 years and older worldwide, and forecasts that number to increase to 39.4 million prevalent cases by 2028.
  • The approved drugs in the gout space focus on targets such as microtubules, URAT1, xanthine oxidase, interleukin-1, and uric acid. These drugs are commonly administered via the oral route, with the remainder being available in intravenous and subcutaneous formulations.
  • The largest proportion of industry-sponsored drugs in active clinical development for gout are in Phase I, with just a single product in Phase III.
  • Drugs in development for gout focus on targets such as uric acid, URAT1, xanthine oxidase, and NLR protein-3/inflammasome. The largest proportion of pipeline drugs are administered via the oral route, with the remainder being intravenous, intramuscular, and topical formulations.
  • High-impact upcoming events for drugs in the gout space comprise topline Phase II trial results for ALLN-346, and topline Phase III trial results for SEL-212.
  • The overall likelihood of approval of a Phase I arthritis asset is 8.8%, and the average probability a drug advances from Phase III is 80%. Drugs, on average, take 9.0 years from Phase I to approval, compared to 9.2 years in the overall autoimmune/immunology space.
  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for gout have been in the early and midphases of development, with 71% of trials in Phase I-II, and 29% in Phase III-IV.
  • The US has a substantial lead in the number of gout clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.
  • Clinical trial activity in the gout space is dominated by completed trials. AstraZeneca has the highest number of completed clinical trials for gout, with 71 trials.
  • AstraZeneca leads industry sponsors with the highest overall number of clinical trials for gout

Table of Contents

OVERVIEWKEY TAKEAWAYS
DISEASE BACKGROUND
  • Subtypes

TREATMENT
  • Non-steroidal anti-inflammatory drugs (NSAIDs)
  • Corticosteroids
  • Colchicine
  • Combination therapy
  • Prevention of chronic gout

EPIDEMIOLOGYMARKETED DRUGSPIPELINE DRUGS
RECENT EVENTS AND ANALYST OPINION
  • SEL-212 for Gout (September 30, 2020)
  • URC102 for Gout (September 27, 2019)

KEY UPCOMING EVENTSPROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
  • Sobi Pays $100m Upfront For Selecta Gout Drug
  • Eisai Acquires Chinese Rights To Fuji Hyperuricemia Drug

REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY
  • Prescription information

APPENDIX
LIST OF FIGURES
Figure 1: Trends in prevalent cases of gout, 2019–28
Figure 2: Overview of pipeline drugs for gout in the US
Figure 3: Pipeline drugs for gout, by company
Figure 4: Pipeline drugs for gout, by drug type
Figure 5: Pipeline drugs for gout, by classification
Figure 6: SEL-212 for Gout (September 30, 2020): Phase II - COMPARE (vs. Krystexxa)
Figure 7: Key upcoming events in gout
Figure 8: Probability of success in the arthritis pipeline
Figure 9: Clinical trials in gout
Figure 10: Top 10 drugs for clinical trials in gout
Figure 11: Top 10 companies for clinical trials in gout
Figure 12: Trial locations in gout
Figure 13: Gout trials status
Figure 14: Gout trials sponsors, by phase
LIST OF TABLES
Table 1: Prevalent cases of gout, 2019–28
Table 2: Marketed drugs for gout
Table 3: Pipeline drugs for gout in the US
Table 4: SEL-212 for Gout (September 30, 2020)
Table 5: URC102 for Gout (September 27, 2019)
Table 6: Historical global sales, by drug ($m), 2015–19
Table 7: Forecasted global sales, by drug ($m), 2021–25